|
|
Vol. 11.10 – 17 March, 2022
|
|
|
|
|
|
|
|
Scientists revealed a role of airway basal cells in tracheobronchopathia osteochondroplastica progression by acting as a repository of inflammatory and TGFβ-BMP signals, which contributed to both epithelial metaplasia and mesenchymal osteo-chondrogenesis via extracellular signaling and matrix remodeling. [Nature Communications]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Researchers showed that in COPD patients, protein arginine methyltransferase 7 (PRMT7) expression was elevated in the lung tissue and localized to the macrophages. [Nature Communications]
|
|
|
|
|
|
The authors demonstrated that YAP/TAZ activation reprogrammed airway secretory cells, which subsequently lost their cellular identity and acquired squamous alveolar type 1 fate in the lung. [EMBO Journal]
|
|
|
|
|
|
Investigators identified a novel circular RNA (circRNA)-ANKRD42 from peripheral blood of patients with idiopathic pulmonary fibrosis, which participated in pulmonary fibrosis through the close communication of mechanical stiffness and biochemical signals. [Molecular Therapy]
|
|
|
|
|
|
Researchers suggested that micro-computed tomography (CT) analyzable pluripotent stem cell (PSC)-derived alveolar human lung organoids were a promising in vitro model to predict lung toxicity manifestations, including fibrosis.
[Cell Biology and Toxicology]
|
|
|
|
|
|
To assess methylation profiles in the main COPD target organ, investigators performed an epigenome-wide association study on bronchoalveolar lavage cells.
[American Journal of Respiratory Cell and Molecular Biology]
|
|
|
|
|
|
The authors established, from single biopsy specimens, a human adult stem cell-derived organoid model representing the upper respiratory airways and lungs and explored the applicability of this model to study respiratory virus infection.
[Frontiers in Cellular and infection Microbiology]
|
|
|
|
|
|
|
|
Scientists established lorlatinib intermediate resistant cells from a patient-derived cell model. Glycogen synthase kinase 3 (GSK3) inhibitions significantly suppressed lorlatinib intermediate resistant cell growth. [npj Precision Oncology]
|
|
|
|
|
|
The authors presented a method for inducing controlled tumor angiogenesis by engineering the microenvironment that could aid in the development of effective anticancer drugs and cancer immunotherapy.
[Advanced Healthcare Materials]
|
|
|
|
|
|
Scientists found that cinobufotalin (CB) decreased cisplatin (DDP) resistance, migration and invasion in lung adenocarcinoma and showed that CB induced ENKUR expression by suppressing PI3K/AKT signaling to downregulate c-Jun, a negative transcription factor of ENKUR.
[Acta Pharmacologica Sinica]
|
|
|
|
|
|
Investigators combined multiple “-omics” methods to assess SWI/SNF composition and aberrations in lung adenocarcinoma (LUAD). Mutations in lung SWI/SNF subunits were highly recurrent in their LUAD cohort, and over 70% of the mutations were predicted to have functional impact. [Clinical Epigenetics]
|
|
|
|
|
|
Researchers explored the metabolic reprogramming relevant to lung adenocarcinoma metastasis and decoded the underlying intercellular alterations.
[Communications Biology]
|
|
|
|
|
|
Investigators demonstrated that AXL was a critical targetable driver of immune suppression in STK11/LKB1 mutant NSCLC.
[Cell Reports Medicine]
|
|
|
|
|
|
|
|
The authors review the advancements in transformed SCLC, including clinical and pathological characteristics, and the potential effective treatment after SCLC transformation, aiming to give a better understanding of transformed SCLC and provide support for clinical uses.
[Seminars in Cancer Biology]
|
|
|
|
|
|
Scientists summarize the roles of distinct immunogenic cell death mechanisms on antitumor immunity and recent advances of ferroptosis-, necroptosis- and pyroptosis-inducing agents, and present perspectives on these cell death mechanisms in immunotherapy of SCLC.
[Seminars in Cancer Biology]
|
|
|
|
|
|
Investigators outline the basic structure and generation characteristic of chimeric antigen receptor-modified T (CAR-T) cells and summarize the common tumor-associated antigens in clinical trials of CAR-T cell therapy for lung cancer.
[Thoracic Cancer]
|
|
|
|
|
|
|
|
Foundation Medicine, Inc. announced it has received approval from the US FDA for FoundationOne®CDx to be used as a companion diagnostic to identify patients with NSCLC.
[Foundation Medicine, Inc.]
|
|
|
|
|
|
Iovance Biotherapeutics, Inc. announced that the US FDA has allowed an IND to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.
[Iovance Biotherapeutics, Inc.]
|
|
|
|
|
|
|
|
April 23 – 26, 2022
Lisbon, Portugal & Online
|
|
|
|
|
|
|
|
|
|
|
Genentech, Inc. – South San Francisco, California, United States
|
|
|
|
|
|
|
Gilead Sciences – Foster City, California, United States
|
|
|
|
|
|
|
Fred Hutchinson Cancer Research Center – Seattle, Washington, United States
|
|
|
|
|
|
|
Berlin Institute of Health – Berlin, Germany
|
|
|
|
|
|
|
Thorax Institute – Nantes, France
|
|
|
|
|
|